Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention.
Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in muscle-invasive bladder cancer. argenx agreed a deal worth up to about $1.15bn for Unnatural Products.
The FDA has approved Sunharbo (asundexian), which it calls the first factor XIa inhibitor to prevent stroke in certain adults. Bayer HealthCare Pharmaceuticals makes the 50 mg tablet. It is used with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack.
In the 12,327-patient OCEANIC-STROKE trial, ischaemic stroke fell 26% versus placebo over a median treatment duration of 14.2 months. Major bleeding was similar overall, but it rose in patients older than 75 and in the first 90 days. The FDA’s Hylton Joffe called it “a meaningful advance” for patients and health care providers seeking “a new option for secondary stroke prevention.”
The FDA has approved AstraZeneca’s Imfinzi (durvalumab) with enfortumab vedotin-ejfv for muscle-invasive bladder cancer. It covers adults who cannot have, or refuse, cisplatin-based chemotherapy. Treatment starts before radical cystectomy, and Imfinzi continues afterwards. The agency approved it six weeks ahead of its goal date.
In the 695-patient VOLGA trial, median event-free survival was not reached, against 12.1 months with surgery alone. The hazard ratio was 0.51 (95% CI 0.38 to 0.67). Enfortumab vedotin carries a boxed warning for serious skin reactions. Its prescribing information names Stevens-Johnson syndrome and toxic epidermal necrolysis.
The FDA has approved Genentech’s Gazyva (obinutuzumab) for adults with primary membranous nephropathy, a kidney disease. It covers adults at risk of disease progression, to induce remission of proteinuria. The agency says it is the first drug approved specifically for the condition. It was listed on our FDA decisions tracker for November.
In the 142-patient phase 3 MAJESTY trial, complete remission at week 104 was 36% with Gazyva against 6% with tacrolimus. The study was open-label. Gazyva carries a boxed warning for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. The most common side effects were infusion reactions and upper respiratory tract infection.
The FDA has approved EMD Serono’s Pimjetmi (pimicotinib) for adults with symptomatic tenosynovial giant cell tumour. It applies where surgical resection may cause worsening functional limitation or severe morbidity. The dose is 50 mg once daily. The review ran under Project Orbis, with the MHRA among the partners.
In the double-blind MANEUVER trial, the objective response rate at week 25 was 56% (95% CI 42 to 68). On placebo it was 3.2% (95% CI 0.1 to 17). Median duration of response was not reached. Warnings include hepatotoxicity and embryo-fetal toxicity.
The rest of this life science news 16 November 2026 roundup covers a UK cancer approval, three deals and a US safety warning.
The MHRA has approved retifanlimab (Zynyz) for adults with squamous cell carcinoma of the anal canal. It covers cancer that cannot be removed by surgery and has spread or returned locally. The approval went to Incyte Biosciences UK Ltd on 5 November 2026 through the International Recognition Procedure.
It is given by 30-minute infusion every four weeks, with carboplatin and paclitaxel for the first six cycles. In a 308-person study, it beat placebo plus chemotherapy on time alive without progression. The MHRA gave no figures. Julian Beach is its Executive Director, Operations. He said the approval “provides a new treatment option for adults whose cancer cannot be removed by surgery.”
argenx has agreed to acquire Unnatural Products (UNP), a peptide discovery company in Santa Cruz, California. The price is $550m in cash upfront plus up to $595m tied to development and regulatory milestones. That totals up to about $1.15bn. argenx already holds a minority stake, whose size is undisclosed.
UNP will operate as argenx’s peptide discovery hub. Closing is expected by the end of the year, subject to customary conditions. Chief Executive Officer Karen Massey said UNP brings “macrocyclic peptide capabilities that are highly complementary to our antibody engineering.” She added it creates “new possibilities for oral and long-acting medicines.”
BioNTech is buying a Rare Pediatric Disease Priority Review Voucher from Scholar Rock for $205m in cash. The asset purchase agreement is dated 9 November 2026, and BioNTech announced the deal on 10 November. Scholar Rock received the voucher on 11 September 2026, when ISEMBYLD (apitegromab-mstn) was approved.
Closing is subject to Hart-Scott-Rodino clearance. Scholar Rock disclosed the agreement in a Form 8-K filing. BioNTech said it will use the voucher for a future filing. That is for a late-stage oncology asset, which it did not name. A priority review voucher entitles its holder to priority review of a later application.
AstraZeneca has acquired Omniose, which is now a wholly owned subsidiary in its Infectious Disease Unit. Financial terms were not disclosed. The companies had worked together under an exclusive three-year collaboration that began in January 2024.
Omniose is a preclinical company with a bioconjugation platform for conjugate vaccines. AstraZeneca’s Benjamin Moutier, Senior Vice President, Infectious Disease, said the platform “represents a differentiated approach to engineering conjugate vaccines.” He added it “strengthens our ability to develop novel vaccines against serious bacterial infections.” Christian Harding, co-founder and CSO, said: “This milestone reflects the work of exceptional and complementary teams.”
The FDA is requiring labelling changes for GLP-1 receptor agonists because of a potential increased risk of an eye condition. The condition is non-arteritic anterior ischaemic optic neuropathy (NAION). The agency announced it on 9 November 2026. It has not identified a mechanism. We covered the warning in our earlier explainer.
A meta-analysis of 126 randomised trials in 134,253 patients found 15 probable NAION events. The rate was 6.4 per 100,000 person-years with GLP-1 drugs and 3.8 with comparators. A Sentinel analysis against DPP-4 inhibitors gave a hazard ratio of 1.43 (95% CI 1.02 to 2.01).
That’s your life science news digest for 16 November 2026, back next Monday with the latest from pharma, biotech and healthcare at www.lifesciencedaily.news.
Catch up on the 9 November news roundup












